| |
rs1205
| |
|---|
|
Variable
|
CC (n = 129)
|
T carriers (n = 198)
|
p-value
|
|---|
|
Age, years
|
55.4 ± 5.3
|
55.7 ± 5.7
|
0.596a
|
|
Time since menopause, years
|
5 (2–10)
|
5 (2–12)
|
0.978a
|
|
Waist circumference, cm
|
|
WC < 88 cm
|
39.5% (73)
|
40.2% (53)
|
0.994b
|
|
WC ≥ 88 cm
|
60.5% (112)
|
59.8% (79)
|
|
Body mass index, kg/m2 (n = 316)c
|
|
< 24.9
|
31.2% (39)
|
36.1% (69)
|
0.633b
|
|
25–30
|
44.8% (56)
|
42.9% (82)
|
|
> 30
|
24.0% (30)
|
20.9% (40)
|
|
SBP, mmHg
|
125.9 ± 17.8
|
126.2 ± 18.7
|
0.902a
|
|
DBP, mmHg
|
80.2 ± 11.5
|
79.7 ± 11.7
|
0.714a
|
|
Total cholesterol, mg/dl
|
207.2 ± 46.1
|
210.5 ± 43.7
|
0.510a
|
|
HDL-c, mg/dl
|
55.7 ± 12.7
|
58.8 ± 14.6
|
0.300a
|
|
LDL-c, mg/dl
|
124.5 ± 40.2
|
127.5 ± 34.5
|
0.476a
|
|
Triglycerides, mg/dl
|
140.7 ± 141.8
|
139.6 ± 118.2
|
0.938a
|
|
Glucose, mg/dl
|
93.1 ± 18.3
|
94.2 ± 24.3
|
0.662a
|
|
HOMA-IR
|
1.7 (1.3–2.3)
|
1.8 (1.2–2.7)
|
0.229a
|
|
Insulin, μUI/ml
|
7.3 (5.7–9.8)
|
8.0 (5.6–11.6)
|
0.354a
|
|
Metabolic syndrome, % (n)
|
31.8% (41)
|
28.1% (55)
|
0.552b
|
|
hs-CRP, mg/l
|
2.1 (1.0–3.9)
|
1.5 (0.63–2.6)
|
0.004a
|
|
IL6, pg/mL (n = 279)c
|
1.13 (0.85–1.79)
|
1.13 (0.76–1.74)
|
0.285a
|
|
HT, % (n)
|
28.7% (37)
|
29.3% (58)
|
0.999b
|
- Values are expressed as (± standard deviation) or median (interquartile range) (25–75%) (aStudent’s t test) or percentage (absolute number) (bχ2 test, with continuity correction when applicable). cNumber of subjects in sub-sample analyses. P-value of nonparametric variables was obtained after logarithmic transformation. SBP systolic blood pressure, DBP diastolic blood pressure, HDL-c high-density lipoprotein cholesterol, LDL-c low-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment, hs-CRP high-sensitivity C-reactive protein, HT hormone therapy, IL6 interleukin 6
